André R Brunoni1, Rodrigo Machado-Vieira2, Bernardo Sampaio-Junior3, Erica L M Vieira4, Leandro Valiengo3, Isabela M Benseñor5, Paulo A Lotufo5, André F Carvalho6, Hyong Jin Cho7, Wagner F Gattaz8, Antonio L Teixeira4. 1. Center for Clinical and Epidemiological Research & Interdisciplinary Center for Applied Neuromodulation (CINA), University Hospital, University of São Paulo, São Paulo, Brazil; Service of Interdisciplinary Neuromodulation (SIN), Department and Institute of Psychiatry, Faculty of Medicine of University of São Paulo, São Paulo, Brazil; Laboratory of Neuroscience (LIM27), Department and Institute of Psychiatry, University of São Paulo, São Paulo, Brazil. Electronic address: Brunoni@usp.br. 2. Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health (NIMH), NIH, Bethesda, MD, USA. 3. Center for Clinical and Epidemiological Research & Interdisciplinary Center for Applied Neuromodulation (CINA), University Hospital, University of São Paulo, São Paulo, Brazil; Service of Interdisciplinary Neuromodulation (SIN), Department and Institute of Psychiatry, Faculty of Medicine of University of São Paulo, São Paulo, Brazil; Laboratory of Neuroscience (LIM27), Department and Institute of Psychiatry, University of São Paulo, São Paulo, Brazil. 4. Division of Neuroscience, Interdisciplinary Laboratory of Medical Investigation (LIIM), School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil. 5. Center for Clinical and Epidemiological Research & Interdisciplinary Center for Applied Neuromodulation (CINA), University Hospital, University of São Paulo, São Paulo, Brazil. 6. Department of Clinical Medicine and Translational Pychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil. 7. Cousins Center for Psychoneuroimmunology, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA. 8. Laboratory of Neuroscience (LIM27), Department and Institute of Psychiatry, University of São Paulo, São Paulo, Brazil.
Abstract
BACKGROUND: The cytokine hypothesis of depression postulates that the pathophysiology of this illness incorporates an increased production of pro-inflammatory cytokines, which leads to an over-activation of the hypothalamic-pituitary-adrenal axis as well as monoaminergic disturbances. Nevertheless, it remains unclear whether the amelioration of depressive symptoms could decrease cytokine levels. Notwithstanding antidepressant drug therapy might exert anti-inflammatory effects, the effects of non-invasive neuromodulatory approaches like transcranial direct current stimulation (tDCS) on pro-inflammatory cytokine networks are largely unknown. METHODS: We evaluated, in the Sertraline vs. Electric Current Therapy for Treating Depression Clinical Study (SELECT-TDCS) trial, whether the plasma levels of the soluble TNF receptors 1 and 2 (sTNFRs) changed after antidepressant treatment in a sample of 73 antidepressant-free patients with unipolar depressive disorder in an episode of at least moderate intensity. RESULTS: Although both tDCS and sertraline exerted antidepressant effects, the plasma levels of sTNFRs did not change over time regardless of the intervention and clinical response. Also, baseline sTNFRs levels did not predict antidepressant response. LIMITATIONS: Our negative findings could be a type II error, as this trial did not use an equivalence design. CONCLUSIONS: To conclude, in this novel placebo-controlled trial prospectively evaluating the changes of sTNFRs in depressed patients, we found that these molecules are not surrogate biomarkers of treatment response of tDCS, whose antidepressant effects occurred regardless of normalization of immunological activity.
RCT Entities:
BACKGROUND: The cytokine hypothesis of depression postulates that the pathophysiology of this illness incorporates an increased production of pro-inflammatory cytokines, which leads to an over-activation of the hypothalamic-pituitary-adrenal axis as well as monoaminergic disturbances. Nevertheless, it remains unclear whether the amelioration of depressive symptoms could decrease cytokine levels. Notwithstanding antidepressant drug therapy might exert anti-inflammatory effects, the effects of non-invasive neuromodulatory approaches like transcranial direct current stimulation (tDCS) on pro-inflammatory cytokine networks are largely unknown. METHODS: We evaluated, in the Sertraline vs. Electric Current Therapy for Treating Depression Clinical Study (SELECT-TDCS) trial, whether the plasma levels of the soluble TNF receptors 1 and 2 (sTNFRs) changed after antidepressant treatment in a sample of 73 antidepressant-free patients with unipolar depressive disorder in an episode of at least moderate intensity. RESULTS: Although both tDCS and sertraline exerted antidepressant effects, the plasma levels of sTNFRs did not change over time regardless of the intervention and clinical response. Also, baseline sTNFRs levels did not predict antidepressant response. LIMITATIONS: Our negative findings could be a type II error, as this trial did not use an equivalence design. CONCLUSIONS: To conclude, in this novel placebo-controlled trial prospectively evaluating the changes of sTNFRs in depressedpatients, we found that these molecules are not surrogate biomarkers of treatment response of tDCS, whose antidepressant effects occurred regardless of normalization of immunological activity.
Authors: Areej El-Jawahri; Yi-Bin Chen; Ruta Brazauskas; Naya He; Stephanie J Lee; Jennifer M Knight; Navneet Majhail; David Buchbinder; Raquel M Schears; Baldeep M Wirk; William A Wood; Ibrahim Ahmed; Mahmoud Aljurf; Jeff Szer; Sara M Beattie; Minoo Battiwalla; Christopher Dandoy; Miguel-Angel Diaz; Anita D'Souza; Cesar O Freytes; James Gajewski; Usama Gergis; Shahrukh K Hashmi; Ann Jakubowski; Rammurti T Kamble; Tamila Kindwall-Keller; Hilard M Lazarus; Adriana K Malone; David I Marks; Kenneth Meehan; Bipin N Savani; Richard F Olsson; David Rizzieri; Amir Steinberg; Dawn Speckhart; David Szwajcer; Helene Schoemans; Sachiko Seo; Celalettin Ustun; Yoshiko Atsuta; Jignesh Dalal; Carmem Sales-Bonfim; Nandita Khera; Theresa Hahn; Wael Saber Journal: Cancer Date: 2017-01-19 Impact factor: 6.860
Authors: Minkyung Park; Laura E Newman; Philip W Gold; David A Luckenbaugh; Peixiong Yuan; Rodrigo Machado-Vieira; Carlos A Zarate Journal: J Psychiatr Res Date: 2016-09-30 Impact factor: 4.791
Authors: Breno S Diniz; Benoit H Mulsant; Charles F Reynolds; Daniel M Blumberger; Jordan F Karp; Meryl A Butters; Ana Paula Mendes-Silva; Erica L Vieira; George Tseng; Eric J Lenze Journal: JAMA Netw Open Date: 2022-06-01